| Fexofenadine | 501.6564
C32H39NO4 |  | A selective H1-antagonist for the symptomatic treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. | Anti-Allergic Agents / Histamine H1 Antagonists / Histamine H1 Antagonists, Non-Sedating |
| Bromocriptine | 654.595
C32H40BrN5O5 |  | A dopamine D2 receptor agonist used for the treatment of galactorrhea due to hyperprolactinemia and other prolactin-related conditions, as well as in early Parkinsonian Syndrome. | Prolactine Inhibitors |
| Sparsentan | 592.76
C32H40N4O5S |  | An endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. | Agents Acting on the Renin-Angiotensin System / Amides / Angiotensin 2 Receptor Blocker / Angiotensin II receptor antagonists / Angiotensin II Type 1 Receptor Blockers / Angiotensin Receptor Antagonists / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA) / Endothelin Receptor Antagonists / OAT3/SLC22A8 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Sulfones / Sulfur Compounds |
| Terfenadine | 471.6734
C32H41NO2 |  | An antihistamine for the treatment of allergy symptoms. | Benzhydryl Compounds / Histamine H1 Antagonists, Non-Sedating / Piperidines |
| Dihydro-alpha-ergocryptine | 577.726
C32H43N5O5 |  | A nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. | Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates |
| Epicriptine | 577.726
C32H43N5O5 |  | A nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. | Alkaloids / Dopamine Agonists |
| Ciclesonide | 540.697
C32H44O7 |  | A glucocorticoid used in the symptomatic relief of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents. | Glucocorticoids |
| Nelfinavir | 567.782
C32H45N3O4S |  | A viral protease inhibitor used in the treatment of HIV infection. | HIV Protease Inhibitors / Isoquinolines / Protease Inhibitors |
| Fulvestrant | 606.78
C32H47F5O3S |  | An estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-. | Anti-Estrogens |
| Estradiol dienanthate | 496.732
C32H48O4 |  | An estrogen used in some combined hormonal oral contraceptives. | BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Inhibitors (weak) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Drugs that are Mainly Renally Excreted / Estradiol Congeners / Estranes / Estrenes / Fused-Ring Compounds / Gonadal Hormones / Gonadal Steroid Hormones / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / OATP1B1/SLCO1B1 Inhibitors / OCT1 inhibitors / OCT2 Inhibitors / Organic Anion Transporting Polypeptide 2B1 Inhibitors / P-glycoprotein substrates / Steroids / UGT1A1 Substrates |
| Steviolbioside | 642.739
C32H50O13 |  | Steviolbioside has been used in trials studying the treatment of HIV-1 Infection. | Stevia / Sweetening Agents |
| Demecarium | 556.7797
C32H52N4O4 |  | For the topical treatment of chronic open-angle glaucoma. | Cholinesterase Inhibitors / Parasympathomimetics |
| Rocuronium | 529.7742
C32H53N2O4 |  | A vecuronium analog used to facilitate tracheal intubation and to relax skeletal muscles during surgery. | Agents producing tachycardia |
| Thonzonium | 511.818
C32H55N4O |  | A cationic surfactant used to disperse exudate and cellular debris, as well as enhance the penetration of antimicrobials. | Amines / Ammonium Compounds / Nitrogen Compounds / Onium Compounds / Surface-Active Agents |
| Telmisartan | 514.6169
C33H30N4O2 |  | An ARB used to treat hypertension, diabetic nephropathy, and congestive heart failure. | Angiotensin II receptor blockers (ARBs) and calcium channel blockers / Angiotensin II receptor blockers (ARBs) and diuretics |
| Candesartan cilexetil | 610.671
C33H34N6O6 |  | An angiotensin receptor blocker used to treat hypertension, systolic hypertension, left ventricular hypertrophy, and delay progression of diabetic nephropathy. | Angiotensin II Antagonists and Diuretics |
| Avacopan | 581.656
C33H35F4N3O2 |  | An orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis. | Selective Immunosuppressants |
| Atorvastatin | 558.6398
C33H35FN2O5 |  | An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke. | Anticholesteremic Agents / Heptanoic Acids / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypolipidemic Agents Indicated for Hyperlipidemia |
| Ergotamine | 581.6615
C33H35N5O5 |  | An alpha-1 selective adrenergic agonist vasoconstrictor used to treat migraines with or without aura and cluster headaches. | Ergot Alkaloids and Derivatives |
| Dihydroergotamine | 583.6774
C33H37N5O5 |  | An ergot alkaloid used in the acute treatment of migraine headache and cluster headache. | Ergot Alkaloids and Derivatives |
| Gadofosveset trisodium | 1003.85
C33H38GdN3Na5O14P |  | An intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease. | Paramagnetic Contrast Media |
| Irinotecan | 586.678
C33H38N4O6 |  | A topoisomerase inhibitor used to treat metastatic carcinoma of the colon or rectum and pancreatic adenocarcinoma. | Topoisomerase 1 (TOP1) inhibitors |
| Glycerol phenylbutyrate | 530.6512
C33H38O6 |  | A nitrogen-binding agent used to manage patients with urea cycle disorders who cannot be sufficiently managed amino acid supplementation and/or dietary restrictions. | Various Alimentary Tract and Metabolism Products |
| Reserpine | 608.6787
C33H40N2O9 |  | For the treatment of hypertension | Secologanin Tryptamine Alkaloids |
| Omaveloxolone | 554.723
C33H44F2N2O3 |  | A semisynthetic triterpenoid used to treat Friedreich’s ataxia in adults and adolescents 16 years and older. | Anti-Inflammatory Agents / Antioxidants / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (weak) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (weak) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / OAT1/SLC22A6 inhibitors / Oxidation-Reduction Agent / Terpenes / Triterpenes |
